Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17


Polyamidoamine (PAMAM) dendrimer conjugate specifically activates the A3 adenosine receptor to improve post-ischemic/reperfusion function in isolated mouse hearts.

Wan TC, Tosh DK, Du L, Gizewski ET, Jacobson KA, Auchampach JA.

BMC Pharmacol. 2011 Oct 31;11:11. doi: 10.1186/1471-2210-11-11.


Predicted structures of agonist and antagonist bound complexes of adenosine A3 receptor.

Kim SK, Riley L, Abrol R, Jacobson KA, Goddard WA 3rd.

Proteins. 2011 Jun;79(6):1878-97. doi: 10.1002/prot.23012. Epub 2011 Apr 12.


International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.

Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE.

Pharmacol Rev. 2011 Mar;63(1):1-34. doi: 10.1124/pr.110.003285. Epub 2011 Feb 8. Review.


Recent developments in adenosine receptor ligands and their potential as novel drugs.

Müller CE, Jacobson KA.

Biochim Biophys Acta. 2011 May;1808(5):1290-308. doi: 10.1016/j.bbamem.2010.12.017. Epub 2010 Dec 23. Review.


Activation of A1, A2A, or A3 adenosine receptors attenuates lung ischemia-reperfusion injury.

Gazoni LM, Walters DM, Unger EB, Linden J, Kron IL, Laubach VE.

J Thorac Cardiovasc Surg. 2010 Aug;140(2):440-6. doi: 10.1016/j.jtcvs.2010.03.002. Epub 2010 Apr 15.


A(3) adenosine receptor activation during reperfusion reduces infarct size through actions on bone marrow-derived cells.

Ge ZD, van der Hoeven D, Maas JE, Wan TC, Auchampach JA.

J Mol Cell Cardiol. 2010 Aug;49(2):280-6. doi: 10.1016/j.yjmcc.2010.01.018. Epub 2010 Feb 2.


Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering.

Jacobson KA, Klutz AM, Tosh DK, Ivanov AA, Preti D, Baraldi PG.

Handb Exp Pharmacol. 2009;(193):123-59. doi: 10.1007/978-3-540-89615-9_5. Review.


Synthesis and characterization of [76Br]-labeled high-affinity A3 adenosine receptor ligands for positron emission tomography.

Kiesewetter DO, Lang L, Ma Y, Bhattacharjee AK, Gao ZG, Joshi BV, Melman A, de Castro S, Jacobson KA.

Nucl Med Biol. 2009 Jan;36(1):3-10. doi: 10.1016/j.nucmedbio.2008.10.003.


Adenosine A3 receptor deficiency exerts unanticipated protective effects on the pressure-overloaded left ventricle.

Lu Z, Fassett J, Xu X, Hu X, Zhu G, French J, Zhang P, Schnermann J, Bache RJ, Chen Y.

Circulation. 2008 Oct 21;118(17):1713-21. doi: 10.1161/CIRCULATIONAHA.108.788307. Epub 2008 Oct 6.


The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats.

Ochaion A, Bar-Yehuda S, Cohen S, Amital H, Jacobson KA, Joshi BV, Gao ZG, Barer F, Patoka R, Del Valle L, Perez-Liz G, Fishman P.

Biochem Pharmacol. 2008 Aug 15;76(4):482-94. doi: 10.1016/j.bcp.2008.05.032. Epub 2008 Jun 17.


Activation of the A(3) adenosine receptor suppresses superoxide production and chemotaxis of mouse bone marrow neutrophils.

van der Hoeven D, Wan TC, Auchampach JA.

Mol Pharmacol. 2008 Sep;74(3):685-96. doi: 10.1124/mol.108.048066. Epub 2008 Jun 26.


The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel.

Wan TC, Ge ZD, Tampo A, Mio Y, Bienengraeber MW, Tracey WR, Gross GJ, Kwok WM, Auchampach JA.

J Pharmacol Exp Ther. 2008 Jan;324(1):234-43. Epub 2007 Sep 28.


Reperfusion injury: does it exist?

Gross GJ, Auchampach JA.

J Mol Cell Cardiol. 2007 Jan;42(1):12-8. Epub 2006 Oct 27. Review.


Adenosine receptors as therapeutic targets.

Jacobson KA, Gao ZG.

Nat Rev Drug Discov. 2006 Mar;5(3):247-64. Review.


Semi-rational design of (north)-methanocarba nucleosides as dual acting A(1) and A(3) adenosine receptor agonists: novel prototypes for cardioprotection.

Jacobson KA, Gao ZG, Tchilibon S, Duong HT, Joshi BV, Sonin D, Liang BT.

J Med Chem. 2005 Dec 29;48(26):8103-7.


(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.

Tchilibon S, Joshi BV, Kim SK, Duong HT, Gao ZG, Jacobson KA.

J Med Chem. 2005 Mar 24;48(6):1745-58.


Modulation of adenosine receptor affinity and intrinsic efficacy in adenine nucleosides substituted at the 2-position.

Ohno M, Gao ZG, Van Rompaey P, Tchilibon S, Kim SK, Harris BA, Gross AS, Duong HT, Van Calenbergh S, Jacobson KA.

Bioorg Med Chem. 2004 Jun 1;12(11):2995-3007.

Supplemental Content

Support Center